Bioavailability and inhibitory effect for stress ulcer of cimetidine polymorphs in rats

Exploring complex transitions between polymorphs on a small scale by coupling AFM, FTIR and DSC: the case of Irganox 1076® antioxidant

“…6,7 For example, because of differences in solubility, one form may be more active therapeutically than another. 1,8 In our case we were interested in the polymorphism of polymer additives, which is a much less studied eld, [9][10][11] but which might have an impact on (i) The surface properties of the polymer. (ii) The leaching of the additive in liquid media in contact with the polymer surface.…”

Understanding Pharmaceutical Polymorphic Transformations II: Crystallization Variables and Influence on Dosage Forms

“…Oral administration of form C exhibited secondary plasma peaks attributable to enhanced frequency and preponement of phase III contractions indicative of mitigating motor complex [89]. Despite these facts, pharmacodynamic evaluation revealed no difference in the ulcer inhibition rate on increasing the dose of form C. On the contrary, better ulcer inhibition was evident on increasing the dose for forms A and B [90].…”

Polymorphism: The Phenomenon Affecting the Performance of Drugs

“…Interestingly, all the forms offered high dissolution behavior within 15 min, which was further stabilized to a constant value after 4 hours [93]. Polymorphic forms are established to alter the biological distribution and efficacy of chloramphenicol palmitate [94], phenylbutazone [95], amobarbitol [27], cimetidine [96], 6-mercaptopurine [26] and chlortetracycline hydrochloride [24]; though established in animal models [97]. Despite preclinical studies, various clinical studies employing polymorphic forms of a variety of drugs is easily traceable.…”